Latest Commercialization News

Sprintex Limited has raised $1.5 million through a strategic placement to advance its ammonia-reduction technology in Europe, supported by pending orders worth €9.3 million. The funding underscores growing investor confidence amid tightening environmental regulations.

Tamboran Resources' Beetaloo Joint Venture has reached a Final Investment Decision for the Shenandoah South Pilot Project, setting the stage for first gas sales by mid-2026. The project secures key commercial agreements and financing, marking a pivotal shift from exploration to production.

Orthocell has appointed its first Canadian distributor for Remplir, its innovative nerve repair device, ahead of an official launch at a major surgical conference in Vancouver. The move marks a significant step in expanding the product’s international footprint.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.

Syntara Limited has reported encouraging Phase 2a results for amsulostat combined with ruxolitinib in treating myelofibrosis, demonstrating sustained symptom improvement and spleen volume reduction over 52 weeks.

Athena Resources has reported outstanding assay and metallurgical results from its Byro South drilling program, revealing high-quality magnetite mineralisation with iron grades exceeding 68%. The company is now advancing towards a maiden resource estimate that could reshape the economics of its Byro Magnetite Project.

Aquirian Limited reports a 16.7% revenue increase alongside key operational advances at its Wubin facility and new leadership appointments, signaling strong momentum in mining services and technology.

Future Metals NL has appointed seasoned resources executive Keith Bowes as Managing Director and CEO, aiming to accelerate development of its flagship Panton and Eileen Bore projects.

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

CurveBeam AI has secured A$6.5 million through an institutional placement and completed a €10 million vendor financing facility to accelerate sales of its HiRise™ CT scanner. The company is also progressing a strategic partnership in China and advancing surgical robot validation.